Abiopharma

🔍 Scali Dominick (Executive)

Company: Ready Capital Corp (RC)

Report Date: 2026-03-02

Detailed Transactions and Holdings:

• Acquired 350,000 shares of Common Stock (Direct)
  Date: 2026-03-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 530,637.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 194,175 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 724,812.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 26,313 shares of Common Stock at $1.74 per share (Direct)
  Date: 2026-03-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 698,499.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Acquired 1,050,000 shares of Performance Stock Units (Derivative)
  Date: 2026-03-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,050,000.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: On March 2, 2026, the reporting person was awarded a special time-based retention award of 350,000 shares of restricted Common Stock under the Ready Capital Corporation 2023 Equity Incentive Plan (the "Plan"). The shares will vest on December 31, 2028, conditioned upon the reporting person's continued employment (with certain exceptions).
• F2: On March 5, 2026, the reporting person was awarded 194,175 shares of restricted Common Stock under the Plan. The shares will vest in equal installments of one-third on March 5, 2027, March 5, 2028 and March 5, 2029, conditioned upon the reporting person's continued employment (with certain exceptions).
• F3: Consists of shares of Common Stock withheld by the Issuer, with approval of the Issuer's Board of Directors, in order to satisfy the tax withholding obligation of the reporting person in connection with the vesting of shares of Common Stock granted on February 22, 2025, February 22, 2024 and February 12, 2023.
• F4: Represents the closing price of the Common Stock on March 13, 2026.
• F5: Each performance stock unit represents a contingent right to receive one share of Common Stock (or an equivalent cash payment, as further described in footnote (6) below).
• F6: On March 2, 2026, the reporting person was awarded a special performance-based retention award of 1,050,000 performance-based restricted stock units ("PSUs") under the Plan. The PSUs may vest in up to ten, approximately equal parts, provided that the 30-day volume weighted average price of the Common Stock equals or exceeds ten, approximately equally spaced milestones between specified points, and further conditioned upon the reporting person's continued employment (with certain exceptions). The PSUs (i) will be settled in shares of Common Stock if the stockholders of the Company approve at the 2026 annual meeting of stockholders ("2026 Annual Meeting") an amendment to the Plan to increase the pool of shares available for grant thereunder (the "Plan Amendment"), or (ii) if the Plan Amendment is not approved by the Company's stockholders at the 2026 Annual Meeting, then the PSUs will be settled in cash based upon the value per share of Common Stock on the applicable vesting date.